JAC Advance Access published online on April 3, 2007
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkm089
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae
1 Dipartimento di Patologia, Sezione di Microbiologia, Università degli Studi di Verona, Strada Le Grazie 8, 37134 Verona, Italy 2 Dipartimento di Biologia Molecolare, Cellulare e Animale, Università degli Studi di Camerino, Via F. Camerini 5, 62032 Camerino, Italy
Received 4 August 2006; returned 19 September 2006; revised 24 January 2007; accepted 5 March 2007
* Corresponding author. Fax: +39-045-58-46-06; E-mail: giuseppe.cornaglia{at}univr.it
Objectives: To test four 16-membered macrolides (josamycin, spiramycin, midecamycin and rokitamycin) along with other compounds in the same class (erythromycin, clarithromycin, roxithromycin and azithromycin) plus clindamycin and telithromycin, against Streptococcus pyogenes and Streptococcus pneumoniae isolates with well-characterized resistance genotypes.
Methods: Four hundred and eighty-six isolates of S. pyogenes and 375 isolates of S. pneumoniae were assayed for their macrolide susceptibilities and investigated by PCR to detect their different erythromycin resistance genes. All strains had been isolated over the period 2002–2003 from specimens of different human origin obtained in 14 different Italian centres.
Results: All 16-membered macrolides showed very low MICs (MIC50s and MIC90s, 
0.06–0.5 mg/L) for the erythromycin-susceptible isolates and for those with the M phenotype, but the telithromycin MICs for the M-type isolates were at least four times higher (MIC90s, 0.5 mg/L). In S. pyogenes, the MIC50s of 16-membered macrolides for the cMLSB isolates were 
256 mg/L, whereas that for telithromycin was 4 mg/L; the MIC50s of 16-membered macrolides and telithromycin ranged from 0.06 to 0.5 mg/L for the iMLSB isolates with erm(A) and from 0.12 to 256 mg/L for those with erm(B). In S. pneumoniae, the MIC50s of the 16-membered macrolides for the cMLSB isolates ranged from 0.5 to 128 mg/L, whereas for the iMLSB isolates their values ranged from 0.06 to 4 mg/L; the MIC50s and MIC90s of telithromycin for both the cMLSB and the iMLSB isolates ranged from 0.06 to 0.12 mg/L.
Conclusions: MICs ranged for all the drugs, except telithromycin, from 0.06 to 256 mg/L, with 15% to 30% resistant S. pyogenes for all drugs tested except clindamycin (8%) and telithromycin (5.4%) and 10% to 40% resistant S. pneumoniae for all drugs tested except telithromycin (0.3%). In both S. pyogenes and S. pneumoniae, erythromycin resistance related to a mef gene meant that telithromycin MICs were definitely higher than in erythromycin-susceptible isolates, although telithromycin susceptibility was preserved in all cases. In S. pyogenes, the activity of both 16-membered macrolides and telithromycin against the iMLSB strains proved to be dependent on the erm gene involved, being greater against isolates with erm(A).
Key Words: antimicrobial resistance surveillance , macrolides , azalides , group A streptococci , GAS
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. F. Shorr and R. C. Owens Jr. Guidelines and quality for community-acquired pneumonia: Measures from the Joint Commission and the Centers for Medicare and Medicaid Services Am. J. Health Syst. Pharm., June 15, 2009; 66(12_Supplement_4): S2 - S7. [Abstract] [Full Text] [PDF]
|
|